Atossa Therapeutics Refines EVANGELINE Study for Enhanced Breast Cancer Treatment Efficiency

Atossa Therapeutics Refines Clinical Trial for Breast Cancer Treatment

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in innovative therapies for breast cancer, announces a significant amendment to its Phase 2 EVANGELINE study investigating (Z)-endoxifen for premenopausal women with early-stage ER+/HER2- breast cancer. This revised study design aims to streamline operations, reduce costs, and expedite the timeline for obtaining objective readouts, which in turn extends the company's operational runway. The adjustments reflect a strategic shift towards enhancing efficiency and financial discipline while maintaining a strong focus on patient safety.

The newly designed EVANGELINE study transitions from a larger cohort of 214 patients to a more focused group of 40-65 participants. The study adopts a single-arm, open-label structure, which will facilitate quicker decision-making. It introduces two distinct cohorts: Cohort A, which targets patients with an initial Ki-67 of greater than 10%, will assess the Week-4 Ki-67 ≤10% rate to provide early insights into treatment effectiveness. Conversely, Cohort B will concentrate on patients with an initial Ki-67 of less than 10% and will evaluate the Week-24 objective response. This approach allows Atossa to concentrate on short-interval endpoints that can inform development decisions effectively while ensuring that patient safety protocols remain unwavering.

CEO Steven Quay emphasizes that these changes are designed to enhance the company's focus on critical clinical outcomes and efficient capital deployment. The revised protocol will not compromise the rigorous safety oversight that has characterized Atossa's clinical programs. The company plans to prioritize New Drug Application (NDA)-enabling activities for (Z)-endoxifen in 2026, reflecting its commitment to advancing its therapeutic pipeline in a manner that is both effective and financially sustainable. Encouragingly, previous data from the EVANGELINE run-in phase, which was presented at the 2024 San Antonio Breast Cancer Symposium, indicated a promising Week-4 Ki-67 ≤10% rate of 86%, underscoring the potential of (Z)-endoxifen as a viable treatment option.

In a broader context, Atossa's strategic recalibration is indicative of the evolving landscape of breast cancer research and treatment. As clinical trials become increasingly complex and resource-intensive, companies like Atossa are compelled to adopt more efficient study designs that not only optimize operational costs but also enhance the likelihood of successful outcomes. The biopharmaceutical industry is witnessing a growing emphasis on patient-centric approaches, where safety and effectiveness guide the development of new therapies. Atossa's commitment to these principles positions it favorably within a competitive market focused on addressing significant unmet medical needs in breast cancer treatment.